Abstracts tagged "Safety issues"

Abstract Number: 2658 • 2016 ACR/ARHP Annual Meeting
Adverse Drug Reactions Due to Disease Modifying Drugs in Patients with Rheumatoid Arthritis
Zulema Rosales Rosado^1,2, Judit Font Urgelles¹, Dalifer Freites Núñez¹, Cynthia Milagros León Cárdenas¹, Cristina Lajas Petisco¹, Leticia Leon², Luis Rodriguez Rodriguez², Juan A Jover Jover¹ and Lydia Abásolo Alcázar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: There is a high risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. After more…
Abstract Number: 244 • 2016 ACR/ARHP Annual Meeting
Leflunomide and Glucocorticoids Combination Therapy for the Induction and Maintenance of Remission in Patients with IgG4-Related Disease
Yiwen Wang¹, Dai Gao¹, Gui Luo², Kunpeng Li¹, Zheng Zhao¹ and Jian Zhu¹, ¹Rheumatology, Chinese PLA General Hospital, Beijing, China, ²Chinese PLA General Hospital, Beijing, China
Background/Purpose: Good response could be observed after applying glucocorticoids (GCs) in patients with IgG4-related disease (IgG4-RD), however, the risk of disease relapse was reported relatively…
Abstract Number: 441 • 2016 ACR/ARHP Annual Meeting
Improving Care and Avoiding Errors. Can Our Patients Recall Their Medications and Create an Accurate Medication List?
Carla F Gamarra-Hilburn and Salvador Vila, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR
Background/Purpose: Medications errors are common and are an important cause of morbidity and mortality. We aimed to evaluate patient accuracy in recalling current medication use,…
Abstract Number: 1641 • 2016 ACR/ARHP Annual Meeting
Survival of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Zulema Rosales Rosado^1,2, Leticia León¹, Dalifer Freites Núñez², Judit Font Urgelles², Cynthia Milagros León Cárdenas², Cristina Vadillo Font², Luis Rodriguez Rodriguez¹, Juan A Jover Jover² and Lydia Abásolo Alcázar¹, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: After more than twenty years using Disease Modifying Drugs (DMARDs) is widely known their efficacy in the treatment of Rheumatoid Arthritis (RA) but it…
Abstract Number: 1076 • 2015 ACR/ARHP Annual Meeting
Safety and Tolerability of Cyclophosphamide Versus Mycophenolate for Systemic Sclerosis-Related Interstitial Lung Disease
Elizabeth R. Volkmann¹, Michael Roth², Robert Elashoff³, Philip J. Clements¹, Daniel E. Furst², Dinesh Khanna⁴, Jonathan Goldin⁵, Donald Tashkin¹ and Scleroderma Lung Study II Group, ¹Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Biomathematics, University of California, Los Angeles, Los Angeles, CA, ⁴Medicine, University of Michigan, Ann Arbor, MI, ⁵David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Although cyclophosphamide (CYC) demonstrated beneficial treatment effects at…
Abstract Number: 2903 • 2015 ACR/ARHP Annual Meeting
Late-Onset Neutropenia Following Rituximab Treatment in Patients with Systemic Lupus Erythematosus
Ioannis Parodis, Frida Söder, Ronald F. van Vollenhoven, Elisabet Svenungsson and Iva Gunnarsson, Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The incidence and clinical consequences of rituximab-mediated late-onset neutropenia (LON) have been studied in various diseases, but data from Systemic Lupus Erythematosus (SLE) are…
Abstract Number: 846 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Arthritis, Anti-Tumor Necrosis Factor Therapy, and Risk of Squamous Cell and Basal Cell Skin Cancer- a Nationwide Population Based Prospective Cohort Study from Sweden
Pauline Raaschou¹, Julia F Simard², Charlotte Asker-Hagelberg³, Johan Askling⁴ and the ARTIS Study group⁵, ¹Karolinska Institutet, Stockholm, Sweden, ²Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, ³Swedish Medical Products Agency, SE-751 03 Uppsala, Sweden, ⁴Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Karolinska Institutet och Svensk Reumatologisk förening, Solna, Sweden
Background/Purpose: There is a concern that tumor necrosis factor inhibitors (TNFi) may interplay with tumor biology and increase the risk of cancer, in particular cancer…
Abstract Number: 481 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Etanercept in Rheumatoid Arthritis Patients over 75 Years Old
Satoru Kodama, Satoshi Ito, Akira Murasawa, Kiyoshi Nakazono and Daisuke Kobayashi, Niigata Rheumatic Center, Shibata, Japan
Background/Purpose Early introductions of biologics in early rheumatoid arthritis (RA) patients are well documented, but there are few reports of biologics use in established elderly…
Abstract Number: 170 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Skin Reactions with Gout Medications: An Analysis of VA Databases
Jasvinder A. Singh¹, Shuo Yang² and Jeff Foster³, ¹University of Alabama and VA Medical Center, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Dermatologic side effects to use of gout treatments are concerning to patients. The goal of the study was to assess the risk of occurrence…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.